Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Eli Lilly Urges European Countries to Improve Alzheimer's Diagnostic Testing

Eli Lilly Urges European Countries to Improve Alzheimer's Diagnostic Testing

Pharmaceutical giant Eli Lilly is calling for urgent improvements in Alzheimer's disease diagnostic testing across Europe, following the recent approval of its Alzheimer's therapy Kisunla on the continent. The company, in collaboration with leading Alzheimer's experts, made this appeal at the Alzheimer Europe Conference, emphasizing the critical need to enhance diagnostic pathways to ensure patients can benefit from new therapeutic innovations.

NoahAI News10/7/2025
Qualtrics to Acquire Press Ganey Forsta for $6.75B, Expanding AI-Powered Healthcare Solutions

Qualtrics to Acquire Press Ganey Forsta for $6.75B, Expanding AI-Powered Healthcare Solutions

Customer engagement company Qualtrics has announced plans to acquire healthcare market research firm Press Ganey Forsta for $6.75 billion, signaling a major shift in the healthcare technology landscape. The deal, expected to close in the coming months, aims to combine Qualtrics' artificial intelligence capabilities with Press Ganey's extensive healthcare expertise and data resources.

NoahAI News10/7/2025
MapLight Therapeutics Aims for $262M IPO to Fund Schizophrenia and Alzheimer's Programs

MapLight Therapeutics Aims for $262M IPO to Fund Schizophrenia and Alzheimer's Programs

MapLight Therapeutics, a California-based biotech company, has unveiled plans for an initial public offering (IPO) on the Nasdaq, aiming to raise up to $262 million. The company intends to use the proceeds to advance its pipeline, with a particular focus on challenging Bristol Myers Squibb's schizophrenia medication, Cobenfy.

NoahAI News10/7/2025
AstraZeneca's Baxdrostat Shows Promise in Phase 3 Hypertension Trial

AstraZeneca's Baxdrostat Shows Promise in Phase 3 Hypertension Trial

AstraZeneca has announced positive results from its latest phase 3 trial for baxdrostat, a novel blood pressure medication, further solidifying the company's position in the competitive hypertension treatment market. The trial's success marks a significant milestone for the pharmaceutical giant, which acquired the drug's developer, CinCor Pharma, in a $1.3 billion upfront deal earlier this year.

NoahAI News10/7/2025
FDA Lifts Clinical Hold on Neurizon's ALS Drug, Clearing Path for Human Trials

FDA Lifts Clinical Hold on Neurizon's ALS Drug, Clearing Path for Human Trials

The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on Neurizon's investigational drug for amyotrophic lateral sclerosis (ALS), paving the way for human trials to begin. The decision, announced by the Melbourne-based biotech company on Monday, marks a significant milestone in the development of NUZ-001, a potential treatment for ALS and other neurodegenerative diseases.

NoahAI News10/7/2025
Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Cost-Cutting Measures

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Cost-Cutting Measures

The pharmaceutical and biotech sectors are experiencing a wave of workforce reductions as companies realign their strategies, prioritize key programs, and aim to extend cash runways in a challenging economic environment.Pharmaceutical giant Merck announced plans to eliminate approximately 6,000 jobs globally, affecting around 8% of its workforce. The layoffs are part of a multiyear process aimed at generating $3 billion in cost savings by 2027. Merck CEO Rob Davis emphasized that these cuts are intended to reallocate resources to support the launch of up to 20 new products.

NoahAI News10/7/2025
Rocket Pharmaceuticals Withdraws Gene Therapy Application for Rare Blood Disorder

Rocket Pharmaceuticals Withdraws Gene Therapy Application for Rare Blood Disorder

Rocket Pharmaceuticals, a New Jersey-based biotech company, has voluntarily withdrawn its biologics license application (BLA) for mozafancogene autotemcel, a gene therapy intended to treat Fanconi anemia, a rare blood disorder. This decision, announced in an SEC filing on October 6, 2025, marks a significant shift in the company's strategic focus and pipeline priorities.

NoahAI News10/7/2025
Atlantic Health and Saint Peter's Healthcare System Cancel Merger Plans Amid Changing Healthcare Landscape

Atlantic Health and Saint Peter's Healthcare System Cancel Merger Plans Amid Changing Healthcare Landscape

In a surprising turn of events, New Jersey-based nonprofit health systems Atlantic Health and Saint Peter's Healthcare System have mutually agreed to terminate their planned merger. The decision, announced on Monday, comes just over a year after the organizations signed a definitive agreement in June 2024.

NoahAI News10/7/2025
Revvity and Sanofi Partner on Early Type 1 Diabetes Detection; Kihealth Secures Funding for Diabetes Test

Revvity and Sanofi Partner on Early Type 1 Diabetes Detection; Kihealth Secures Funding for Diabetes Test

Significant developments in diabetes screening and detection have emerged this week, with major pharmaceutical companies and startups alike making strides in early diagnosis technologies.Revvity, the Massachusetts-based diagnostics company, has announced a collaboration with pharmaceutical giant Sanofi to develop a cutting-edge screening test for early-stage Type 1 diabetes. The partnership aims to improve patient outcomes by enabling earlier intervention in the disease's progression.

NoahAI News10/7/2025
TCG Crossover Secures $1.3 Billion in Third Fund, Bolstering Life Sciences Investment

TCG Crossover Secures $1.3 Billion in Third Fund, Bolstering Life Sciences Investment

TCG Crossover (TCGX), a prominent bicoastal life sciences investment firm, has successfully closed its third fund, raising $1.3 billion and bringing its total capital to an impressive $3.1 billion. This latest financial milestone, announced on October 6, 2025, underscores the firm's growing influence in the biotechnology investment landscape and its commitment to backing innovative healthcare companies.

NoahAI News10/7/2025
AstraZeneca and Daiichi Sankyo's Datroway Achieves Landmark Results in Triple-Negative Breast Cancer Trial

AstraZeneca and Daiichi Sankyo's Datroway Achieves Landmark Results in Triple-Negative Breast Cancer Trial

AstraZeneca and Daiichi Sankyo have announced groundbreaking results for their antibody-drug conjugate (ADC) Datroway in the treatment of triple-negative breast cancer (TNBC), marking a significant advancement in the field of oncology.In a phase 3 trial, Datroway demonstrated statistically significant and clinically meaningful improvements in both overall survival (OS) and progression-free survival (PFS) compared to standard chemotherapy. This achievement marks the first time a cancer drug has shown an overall survival benefit against chemotherapy for patients with locally recurrent inoperable or metastatic TNBC who are ineligible for immunotherapy.

NoahAI News10/7/2025
Amgen Launches Direct-to-Consumer Platform with Significant Repatha Discount

Amgen Launches Direct-to-Consumer Platform with Significant Repatha Discount

Amgen, a leading pharmaceutical company, has unveiled a new direct-to-consumer (DTC) platform called "AmgenNow," featuring a substantial discount on its cholesterol-lowering drug Repatha. This move aligns with recent industry trends and the Trump Administration's efforts to reduce drug prices in the United States.

NoahAI News10/7/2025
«1...515253...67»